Remarkably, in prostate cancer, where tumor cells do not express CD40 (22) and capable of escaping the immune system by downregulating the class I APCs, like dendritic cell and macrophages (23), a combination treatment of 5 Gy of RT+IBM demonstrates major reduction of tumor volumes in androgen-deprived prostate cancers created by AD-TRAMP-C1 cells. The gene discussed is CD40; the disease is prostate carcinoma.